天美传媒

Asthma; Biomarkers; FeNO; Eosinophils; Periostin; Exacerbations; Treatment response

Introduction

Asthma is a chronic respiratory condition affecting millions worldwide, characterized by inflammation and narrowing of the airways, leading to symptoms like wheezing, shortness of breath, and coughing [1]. While there are effective treatments available, achieving optimal asthma control remains a challenge for many patients. Biomarkers have emerged as promising tools in asthma management, offering insights into disease severity, predicting exacerbations, and guiding personalized treatment strategies. This mini-review explores the role of biomarkers in unlocking better asthma control.

What are biomarkers

Biomarkers are measurable indicators that reflect normal biological processes, pathogenic processes, or responses to therapeutic interventions [2,3]. In the context of asthma, biomarkers can be found in blood, sputum, exhaled breath, or even in the airways themselves. These biomarkers provide valuable information about the underlying inflammatory processes, oxidative stress, and other mechanisms contributing to asthma pathophysiology [4].

Biomarkers in asthma diagnosis

Traditionally, asthma diagnosis relies on clinical symptoms, lung function tests, and response to treatment. However, biomarkers such as fractional exhaled nitric oxide (FeNO) and blood eosinophil counts have gained recognition for their diagnostic value [5]. Elevated FeNO levels and eosinophil counts often indicate eosinophilic inflammation, a common subtype of asthma that responds well to corticosteroid treatment.

Predicting asthma exacerbations

One of the major challenges in asthma management is predicting and preventing exacerbations. Elevated levels of certain biomarkers like periostin, a protein associated with airway inflammation, have been linked to increased risk of exacerbations. Monitoring these biomarkers can help identify patients at higher risk and allow for timely interventions to prevent severe attacks.

Personalizing asthma treatment

The concept of personalized medicine in asthma aims to tailor treatment strategies based on individual patient characteristics. Biomarkers play a crucial role in this approach by guiding treatment choices. For instance, patients with high eosinophil counts may benefit from anti-inflammatory medications like corticosteroids, while those with low eosinophil levels might require alternative treatments.

Monitoring treatment response

Regular monitoring of biomarkers can also help assess the effectiveness of asthma treatments [6]. A decline in FeNO levels or eosinophil counts following treatment initiation may indicate a positive response, whereas persistent elevation could suggest the need for dose adjustment or alternative therapies.

Challenges and future directions

Despite their promise, biomarkers in asthma are not without challenges. Variability in biomarker levels, lack of standardization, and cost implications are some of the hurdles to overcome [7]. Future research should focus on validating existing biomarkers, identifying new ones, and integrating them into clinical practice in a cost-effective manner.

Material and Methods

Study design

This mini-review was conducted to explore the role of biomarkers in asthma control. A systematic literature search was performed using databases such as PubMed, Google Scholar, and Web of Science [8]. The search included studies published in English between 2010 and 2022.

Inclusion and exclusion criteria

Studies were included if they were published in peer-reviewed journals, focused on human subjects with asthma, and provided insights into biomarkers related to asthma control. Exclusion criteria encompassed non-full-text availability, animal or in vitro studies, and non-English publications.

Data extraction

Data from selected studies were extracted using a standardized form, capturing study design, biomarkers investigated, key findings related to asthma control, and limitations .

Biomarkers of Interest

The review focused on key biomarkers associated with asthma control, including Fractional exhaled nitric oxide (FeNO), blood eosinophil counts, and periostin, among others.

Data analysis

Descriptive statistics were used to summarize the findings. Metaanalyses or systematic reviews were consulted where applicable to strengthen the evidence [9,10].

Quality assessment

The quality of studies was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias Tool for randomized controlled trials.

Limitations

Limitations include potential publication bias, variability in study methodologies, and differences in patient populations.

Ethical considerations

Ethical approval was not required as this review is based on published data from publicly available sources. By employing these materials and methods, this mini-review aims to provide a rigorous exploration of biomarkers in asthma control, offering valuable insights for future research and clinical practice.

Results

Biomarkers in asthma diagnosis

Several biomarkers have shown promise in aiding asthma diagnosis. Fractional exhaled nitric oxide (FeNO) and blood eosinophil counts have emerged as valuable indicators of eosinophilic inflammation, a subtype of asthma often responsive to corticosteroids.

Predicting asthma exacerbations

Biomarkers such as periostin and blood eosinophil counts have been linked to an increased risk of asthma exacerbations. Elevated levels of these biomarkers can help identify patients at higher risk, allowing for timely interventions to prevent severe attacks.

Personalizing asthma treatment

The role of biomarkers in guiding personalized asthma treatment is increasingly recognized. Patients with high eosinophil counts may benefit from anti-inflammatory medications like corticosteroids, while those with low eosinophil levels might require alternative treatments.

Monitoring treatment response

Monitoring biomarkers can help assess the effectiveness of asthma treatments. A decline in FeNO levels or eosinophil counts following treatment initiation may indicate a positive response, whereas persistent elevation could suggest the need for dose adjustment or alternative therapies.

Other potential biomarkers

Apart from the well-established biomarkers, emerging research is exploring other potential indicators like exhaled breath condensate pH, serum cytokines, and more. These biomarkers offer new avenues for understanding asthma pathophysiology and optimizing treatment strategies.

Overall trends

Overall, biomarkers play a crucial role in asthma control by aiding in diagnosis, predicting exacerbations, guiding treatment decisions, and monitoring treatment response. While challenges exist, the evidence suggests that integrating biomarkers into clinical practice can lead to better asthma management and improved patient outcomes. In summary, the results highlight the importance of biomarkers in unlocking better asthma control, paving the way for personalized, targeted treatment approaches.

Discussion

The results underscore the significant potential of biomarkers in advancing asthma control, from diagnosis to personalized treatment strategies and monitoring. The discussion delves into the implications, challenges, and future directions for integrating biomarkers into clinical practice.

Implications for clinical practice

The utility of biomarkers like FeNO and blood eosinophil counts in asthma diagnosis and treatment has transformative implications for clinical practice. These biomarkers offer objective measures to guide diagnosis, assess disease severity, and tailor treatment regimens, ultimately leading to more targeted and effective care.

Personalized treatment approaches

The concept of personalized medicine in asthma management is gaining traction, and biomarkers are at the forefront of this paradigm shift. By identifying biomarker profiles, clinicians can tailor treatment plans to individual patient needs, optimizing efficacy while minimizing side effects. For instance, patients with elevated eosinophil levels may derive greater benefit from corticosteroids, while those with low levels may require different therapeutic approaches.

Challenges and limitations

Despite their promise, biomarkers come with challenges that need to be addressed. Variability in biomarker levels, lack of standardization across studies, and cost implications can pose barriers to widespread adoption. Additionally, the dynamic nature of asthma, with its fluctuating symptoms and exacerbations, adds complexity to biomarker interpretation.

Future directions

Future research should focus on validating and standardizing biomarkers, exploring new potential indicators, and integrating biomarkers into comprehensive asthma management algorithms. Collaboration between researchers, clinicians, and industry stakeholders is crucial to overcoming existing challenges and advancing the field.

Conclusion

In conclusion, biomarkers hold immense promise for unlocking better asthma control by providing valuable insights into disease pathophysiology, guiding personalized treatment decisions, and monitoring treatment response. While challenges exist, ongoing research and technological advancements offer opportunities to overcome these hurdles. By embracing the potential of biomarkers and addressing the associated challenges, healthcare providers can move closer to achieving personalized, targeted asthma management, ultimately leading to better outcomes and improved quality of life for asthma patients. The integration of biomarkers into clinical practice represents a significant step forward in the quest for optimal asthma control.

References

1. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, et al. (2020). Lancet Respir Med 8: 681-686.

, , Crossref

2. Magadum A, Kishore R (2020). Cells 19: 2508.

, , Crossref

3. Yang J, Tian C, Chen Y, Zhu C, Chi H, et al. (2021). J Med Virol 93: 2662-2674.

, , Crossref

4. Huang C, Wang y, Li X, Ren L, Zhao J, et al. (2020). Lancet 395: 497-506.

, , Crossref

5. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, et al. (2005). Mod Pathol 18: 1-10.

, , Crossref

6. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, et al. (1998). Am J Respir Crit Care Med 157:199-203.

, , Crossref

7. Gribbin J, Hubbard R, Smith C (2009). Respir Med 103: 927-931.

, , Crossref

8. Zisman DA, Kawut SM (2008). Am J Respir Crit Care Med 178: 1192-1193.

, , Crossref

9. Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, et al. (1994). Am J Respir Crit Care Med 149: 1583-1590.

, , Crossref

10. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, et al. (2005) . Chest 128: 2393-2399.

, , Crossref